publication . Article . 2012

Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe.

Guo, Ning; Ma, Ying; Jacboson, Orit; Lee, Seulki; Niu, Gang; Chen, Xiaoyuan; Zhu, Lei; Li, Quanzheng; Choi, Hak Soo; Mansfield, James R.;
Open Access English
  • Published: 01 Aug 2012 Journal: Theranostics, volume 2, issue 8, pages 746-756 (eissn: 1838-7640, Copyright policy)
  • Publisher: Ivyspring International Publisher
  • Country: United States
Abstract
<p><b>Purpose:</b> The aim of this study is to determine if dynamic optical imaging could provide comparable kinetic parameters to that of dynamic PET imaging by a near-infrared dye/<sup>64</sup>Cu dual-labeled cyclic RGD peptide.</p><p><b>Methods:</b> The integrin &#945;<sub>v</sub>&#946;<sub>3</sub> binding RGD peptide was conjugated with a macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for copper labeling and PET imaging and a near-infrared dye ZW-1 for optical imaging. The <i>in vitro</i> biological activity of RGD-C(DOTA)-ZW-1 was characterized by cell staining and receptor binding assay. Sixty-min dynamic PET and optic...
Subjects
free text keywords: Research Paper, dual modality imaging, dynamic imaging, kinetic modeling, Singular value decomposition (SVD), integrin αvβ3, RGD peptide., Medicine, R, Medicine (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), In vivo, Biomedical engineering, Nanotechnology, Ligand (biochemistry), DOTA, chemistry.chemical_compound, chemistry, 3D optical data storage, Compartment (ship), Binding potential, Analytical chemistry, Peptide, chemistry.chemical_classification, Biology
41 references, page 1 of 3

Cai, W, Rao, J, Gambhir, SS, Chen, X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006; 5: 2624-33 [PubMed]

Delbeke, D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999; 40: 591-603 [PubMed]

Bomanji, JB, Costa, DC, Ell, PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001; 2: 157-64 [OpenAIRE] [PubMed]

La Fougere, C, Suchorska, B, Bartenstein, P, Kreth, FW, Tonn, JC. Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol. 2011; 13: 806-19 [OpenAIRE] [PubMed]

Phelps, ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41: 661-81 [PubMed]

Cai, W, Chen, X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 (Suppl 2): 113S-28S [PubMed]

Ye, Y, Chen, X. Integrin targeting for tumor optical imaging. Theranostics. 2011; 1: 102-26 [OpenAIRE] [PubMed]

Hoshi, Y. Functional near-infrared optical imaging: Utility and limitations in human brain mapping. Psychophysiology. 2003; 40: 511-20 [PubMed]

Shah, K, Weissleder, R. Molecular optical imaging: Applications leading to the development of present day therapeutics. NeuroRx. 2005; 2: 215-25 [OpenAIRE] [PubMed]

Ntziachristos, V, Bremer, C, Weissleder, R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13: 195-208 [OpenAIRE] [PubMed]

Zhu, L, Niu, G, Fang, X, Chen, X. Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging. 2010; 54: 291-308 [OpenAIRE] [PubMed]

Niu, G, Chen, X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47 [OpenAIRE] [PubMed]

Carter, A. Integrins as target: First phase III trial launches, but questions remain. J Natl Cancer Inst. 2010; 102: 675-7 [PubMed]

Millard, M, Odde, S, Neamati, N. Integrin Targeted Therapeutics. Theranostics. 2011; 1: 154-188 [OpenAIRE] [PubMed]

Schottelius, M, Laufer, B, Kessler, H, Wester, HJ. Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res. 2009; 42: 969-80 [OpenAIRE] [PubMed]

41 references, page 1 of 3
Abstract
<p><b>Purpose:</b> The aim of this study is to determine if dynamic optical imaging could provide comparable kinetic parameters to that of dynamic PET imaging by a near-infrared dye/<sup>64</sup>Cu dual-labeled cyclic RGD peptide.</p><p><b>Methods:</b> The integrin &#945;<sub>v</sub>&#946;<sub>3</sub> binding RGD peptide was conjugated with a macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for copper labeling and PET imaging and a near-infrared dye ZW-1 for optical imaging. The <i>in vitro</i> biological activity of RGD-C(DOTA)-ZW-1 was characterized by cell staining and receptor binding assay. Sixty-min dynamic PET and optic...
Subjects
free text keywords: Research Paper, dual modality imaging, dynamic imaging, kinetic modeling, Singular value decomposition (SVD), integrin αvβ3, RGD peptide., Medicine, R, Medicine (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), In vivo, Biomedical engineering, Nanotechnology, Ligand (biochemistry), DOTA, chemistry.chemical_compound, chemistry, 3D optical data storage, Compartment (ship), Binding potential, Analytical chemistry, Peptide, chemistry.chemical_classification, Biology
41 references, page 1 of 3

Cai, W, Rao, J, Gambhir, SS, Chen, X. How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther. 2006; 5: 2624-33 [PubMed]

Delbeke, D. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999; 40: 591-603 [PubMed]

Bomanji, JB, Costa, DC, Ell, PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001; 2: 157-64 [OpenAIRE] [PubMed]

La Fougere, C, Suchorska, B, Bartenstein, P, Kreth, FW, Tonn, JC. Molecular imaging of gliomas with PET: Opportunities and limitations. Neuro Oncol. 2011; 13: 806-19 [OpenAIRE] [PubMed]

Phelps, ME. PET: The merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41: 661-81 [PubMed]

Cai, W, Chen, X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med. 2008; 49 (Suppl 2): 113S-28S [PubMed]

Ye, Y, Chen, X. Integrin targeting for tumor optical imaging. Theranostics. 2011; 1: 102-26 [OpenAIRE] [PubMed]

Hoshi, Y. Functional near-infrared optical imaging: Utility and limitations in human brain mapping. Psychophysiology. 2003; 40: 511-20 [PubMed]

Shah, K, Weissleder, R. Molecular optical imaging: Applications leading to the development of present day therapeutics. NeuroRx. 2005; 2: 215-25 [OpenAIRE] [PubMed]

Ntziachristos, V, Bremer, C, Weissleder, R. Fluorescence imaging with near-infrared light: New technological advances that enable in vivo molecular imaging. Eur Radiol. 2003; 13: 195-208 [OpenAIRE] [PubMed]

Zhu, L, Niu, G, Fang, X, Chen, X. Preclinical molecular imaging of tumor angiogenesis. Q J Nucl Med Mol Imaging. 2010; 54: 291-308 [OpenAIRE] [PubMed]

Niu, G, Chen, X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011; 1: 30-47 [OpenAIRE] [PubMed]

Carter, A. Integrins as target: First phase III trial launches, but questions remain. J Natl Cancer Inst. 2010; 102: 675-7 [PubMed]

Millard, M, Odde, S, Neamati, N. Integrin Targeted Therapeutics. Theranostics. 2011; 1: 154-188 [OpenAIRE] [PubMed]

Schottelius, M, Laufer, B, Kessler, H, Wester, HJ. Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res. 2009; 42: 969-80 [OpenAIRE] [PubMed]

41 references, page 1 of 3
Powered by OpenAIRE Open Research Graph
Any information missing or wrong?Report an Issue
publication . Article . 2012

Dynamic PET and Optical Imaging and Compartment Modeling using a Dual-labeled Cyclic RGD Peptide Probe.

Guo, Ning; Ma, Ying; Jacboson, Orit; Lee, Seulki; Niu, Gang; Chen, Xiaoyuan; Zhu, Lei; Li, Quanzheng; Choi, Hak Soo; Mansfield, James R.;